FDA Panel Recommends Moderna's mRNA Flu Vaccine for Older Adults
A first-of-its-kind flu shot is a step closer to being available to the public after a Food and Drug Administration (FDA) advisory panel voted Thursday to recommend Moderna’s mRNA-based vaccine for approval. The FDA’s independent vaccine advisors voted unanimously 9-0 that the benefits outweigh the risks for Moderna’s mFlusiva shot in people ages 50 to 64 as well as 65 and older. Moderna is seeking...
An advisory panel for the Food and Drug Administration (FDA) has unanimously recommended Moderna's mRNA-based flu vaccine for approval, marking a significant step for this novel preventative measure. The panel voted 9-0, concluding that the benefits of Moderna's mFlusiva vaccine outweigh the risks for individuals aged 50 and older, including those 65 and above. This recommendation paves the way for potential public availability of a new type of flu shot. Moderna is seeking approval for this vaccine, which represents a new approach to seasonal flu prevention.
The FDA panel's recommendation for Moderna's mRNA flu vaccine could lead to a new, potentially more effective, option for protecting older adults against seasonal influenza.
📌 Kaynak
Bu haber XML kaynağından derlenmiştir. Tamamı için orijinal habere gidin.
Orijinal haberi oku →